Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
6 results
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi®▼, AstraZeneca UK Limited).
Br J Cancer. 2020 Dec;123(Suppl 1):18-27. doi: 10.1038/s41416-020-01071-5.
Br J Cancer. 2020.
PMID: 33293672
Free PMC article.
Review.
The current treatment landscape in the UK for stage III NSCLC.
Evison M; AstraZeneca UK Limited.
Evison M, et al.
Br J Cancer. 2020 Dec;123(Suppl 1):3-9. doi: 10.1038/s41416-020-01069-z.
Br J Cancer. 2020.
PMID: 33293670
Free PMC article.
Review.
Item in Clipboard
Rationale for concurrent chemoradiotherapy for patients with stage III non-small-cell lung cancer.
Conibear J; AstraZeneca UK Limited.
Conibear J, et al.
Br J Cancer. 2020 Dec;123(Suppl 1):10-17. doi: 10.1038/s41416-020-01070-6.
Br J Cancer. 2020.
PMID: 33293671
Free PMC article.
Review.
Item in Clipboard
Summary of 'The current status and future perspectives on the management of stage III NSCLC: a focus on unresectable cancer treatment paradigms'.
Paz-Ares L; AstraZeneca UK Limited.
Paz-Ares L, et al.
Br J Cancer. 2020 Dec;123(Suppl 1):36. doi: 10.1038/s41416-020-01073-3.
Br J Cancer. 2020.
PMID: 33293674
Free PMC article.
No abstract available.
Item in Clipboard
Foreword to 'The current status and future perspectives on the management of stage III NSCLC: a focus on unresectable cancer treatment paradigms'.
Paz-Ares L; AstraZeneca UK Limited.
Paz-Ares L, et al.
Br J Cancer. 2020 Dec;123(Suppl 1):1-2. doi: 10.1038/s41416-020-01068-0.
Br J Cancer. 2020.
PMID: 33293669
Free PMC article.
No abstract available.
Item in Clipboard
Practical implications to contemplate when considering radical therapy for stage III non-small-cell lung cancer.
Storey CL, Hanna GG, Greystoke A; AstraZeneca UK Limited.
Storey CL, et al.
Br J Cancer. 2020 Dec;123(Suppl 1):28-35. doi: 10.1038/s41416-020-01072-4.
Br J Cancer. 2020.
PMID: 33293673
Free PMC article.
Review.
Item in Clipboard
Cite
Cite